FTRE
Company Description
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. It operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum. The Enabling Services segment provides patient access and clinical trial technology solutions to customers that streamline complex randomization and optimize the trial drug supply process. The company offers delivery models that include full service, functional service provider, and hybrid service structures. It also offers phase I-IV clinical trial management, differentiated technology enabled trial solutions, and post approval services. The company serves pharmaceutical, biotechnology, and medical device organizations. Fortrea Holdings Inc. was incorporated in 2023 and is based in Durham, North Carolina.
Track Record
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | 2.72B | 2.70B | 2.84B | 2.84B | 3.06B | 2.58B |
| Net Income | (986.20M) | (328.50M) | (25.20M) | 186.20M | 98.00M | (359.20M) |
| EPS | -10.81 | -3.67 | -0.04 | 2.11 | 1.11 | -4.06 |
| Free Cash Flow | 88.30M | 237.30M | 128.10M | 28.30M | 143.30M | 176.90M |
| FCF / Share | 0.97 | 2.65 | 1.44 | 0.32 | 1.62 | 2.00 |
| Operating CF | 113.50M | 262.80M | 168.40M | 82.70M | 169.80M | 200.90M |
| Total Assets | 2.72B | 3.58B | 4.33B | 4.29B | 4.37B | N/A |
| Total Debt | 68.00M | 1.20B | 1.67B | 63.40M | 77.20M | N/A |
| Cash & Equiv | 174.60M | 118.50M | 108.60M | 112.00M | 94.60M | N/A |
| Book Value | 563.50M | 1.36B | 1.71B | 3.34B | 3.26B | N/A |
| Return on Equity | -1.75 | -0.24 | -0.01 | 0.06 | 0.03 | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 636.50M | 660.50M | 701.30M | 710.30M | 651.30M | 697.00M | 674.90M | 662.40M | 662.10M | 775.40M | 713.80M | 725.10M |
| Net Income | (23.60M) | (32.50M) | (15.90M) | (374.90M) | (562.90M) | (61.20M) | (27.90M) | (138.40M) | (101.00M) | (36.00M) | (14.00M) | 30.80M |
| EPS | -0.26 | -0.36 | -0.17 | -4.14 | -6.30 | -0.68 | -0.31 | -1.55 | -1.15 | -0.41 | -0.15 | 0.32 |
| Free Cash Flow | (25.00M) | 121.60M | 79.50M | 14.30M | (127.10M) | 20.30M | (10.60M) | 262.50M | (34.90M) | 3.00M | (3.20M) | 140.50M |
| FCF / Share | -0.27 | 1.33 | 0.87 | 0.16 | -1.42 | 0.23 | -0.12 | 2.94 | -0.39 | 0.03 | -0.04 | 1.58 |
| Operating CF | (17.00M) | 129.10M | 86.80M | 21.80M | (124.20M) | 17.10M | (2.40M) | 273.70M | (25.60M) | 12.40M | 1.90M | 150.10M |
| Total Assets | 2.68B | 2.72B | 2.74B | 2.84B | 3.12B | 3.58B | 3.66B | 3.57B | 4.24B | 4.33B | 4.32B | 4.36B |
| Total Debt | 75.40M | 68.00M | 1.19B | 1.24B | 1.29B | 1.20B | 1.20B | 1.20B | 1.69B | 1.67B | 1.69B | 1.68B |
| Cash & Equiv | 147.50M | 174.60M | 131.30M | 81.20M | 101.60M | 118.50M | 105.30M | 126.20M | 92.80M | 108.60M | 107.50M | 114.30M |
| Book Value | 525.90M | 563.50M | 580.80M | 589.20M | 858.80M | 1.36B | 1.51B | 1.46B | 1.59B | 1.71B | 1.69B | 1.75B |
| Return on Equity | -0.04 | -0.06 | -0.03 | -0.64 | -0.66 | -0.04 | -0.02 | -0.09 | -0.06 | -0.02 | -0.01 | 0.02 |